Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pataday Extra Strength** is an over-the-counter ophthalmic antihistamine product developed and manufactured by **Alcon Vision** for the temporary relief of allergic eye itch associated with allergic conjunctivitis. It contains **olopatadine hydrochloride 0.7%**, a **small-molecule** selective histamine receptor antagonist with mast cell-stabilizing anti-allergic activity, administered as a **once-daily ophthalmic solution**. The product is the highest-strength formulation in the Pataday line and was transitioned from the former prescription brand **Pazeo** to OTC status for 24-hour relief of ocular itching triggered by allergens such as pollen, ragweed, grass, animal hair, and dander.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pataday Extra Strength.